CHEK1 and neoplasm: The preclinical data discussed in earlier sections of this review demonstrate that the ATR-CHK1 axis is an attractive target in cancer treatment as chemo- or radio-sensitisers, in combination with molecularly targeted drugs or as single agents in tumours with the appropriate molecular pathology.